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in BAV patients more frequently than echocardiography 
(96 versus 73 %); CMR appeared to be more sensitive for 
detecting of BAV whereas echocardiography appeared to be 
more specific. Among unselected patients with severe aortic 
valve stenosis, a high percentage of patients with BAV was 
found (40 %). Patients with BAV are significantly younger 
and more frequently male. Typically, the ascending aorta 
was larger in patients with BAV. From a cost-effectiveness 
perspective, echocardiography will still be the first choice 
in BAV patients. When the echocardiograms are difficult to 
analyse or when in doubt, CMR can be useful to come to a 
diagnosis. In a recent study, CMR was found to be superior 
to transthoracic echocardiography for imaging of the aorta in 
patients with congenital aortic stenosis and BAV, especially 
at the level of the proximal ascending aorta when an aor-
tic aneurysm is present [6]. In particular, when the ascend-
ing aorta appears large at echocardiography, it is important 
to evaluate progression of the aortic diameters with CMR 
as standard care [7, 8]. At present, multi-slice computed 
tomography (MSCT) is increasingly used for sizing TAV 
and BAV through noninvasive evaluation of the aortic root 
[9–11]. However, the true gold standard for assessing these 
stenotic valves appears to be the appraisal of the surgeon.
Latest interventional treatment
Currently, BAV stenosis and/or regurgitation is the most 
common indication for surgical aortic valve replacement 
in patients < 70 years of age. Nonetheless, 20 % of patients 
> 80 years of age have underlying bicuspid pathology. Over 
the past 10 years, transcatheter aortic valve replacement 
(TAVR) has become a standard procedure in elderly patients 
with severe inoperable aortic stenosis [12]. Recently, a 
study by Mylotte et al., published in JACC [13], evaluated 
Bicuspid aortic valve (BAV) is one of the most common 
congenital heart defects with a population prevalence of 0.5 
to 1.3 % [1]. The defect is considered to be a heritable dis-
order with a family recurrence rate of approximately 35 %. 
Recent studies show that mutations in the NOTCH1 gene 
are associated with BAV [2]. BAV progresses more rapidly 
into regurgitation or stenosis of the valve [3]. This results 
in a higher occurrence of aortic valve replacement, espe-
cially at younger age. Additionally, BAV is more susceptible 
than a tricuspid aortic valve (TAV) to nest bacteria or other 
organisms, leading to endocarditis. BAV is not only a pecu-
liar valve morphology leading to specific valve pathology, it 
is also frequently associated with (asymptomatic) ascending 
aorta dilatation which leads to an increased susceptibility to 
ascending aortic aneurysms and aortic dissection [4]. Aortic 
elasticity measurements of BAV patients suggest that dimin-
ished aortic elasticity is at least part of its causation.
Optimal diagnosis
Patients with BAV frequently remain undiagnosed until the 
manifestation of symptoms. Therefore, early screening and 
detection of patients is warranted. Imaging of a severely 
stenotic aortic valve is challenging. Due to the severity of 
stenosis and calcified nature of the aortic valves, echocar-
diography is frequently unable to differentiate between TAV 
and BAV. In a previous study published in the Netherlands 
Heart Journal in 2011 [5], cardiovascular magnetic reso-
nance (CMR) was able to assess aortic valve morphology 
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the clinical value of TAVR in 139 BAV patients (mean age 
78.0 ± 8.9 years) from 12 centres in Europe and Canada, 
being the largest collection of BAV patients treated with 
TAVR. Evaluation of the morphology of the aortic valve 
was performed using transoesophageal echocardiogra-
phy in all patients; MSCT-based TAV sizing was used in 
63.5 % of patients. Thirty-day device safety, success, and 
efficacy were noted in 79.1, 89.9, and 84.9 % of patients, 
respectively. There was a 30-day mortality rate of 5 %, a 
30-day stoke rate of 2 %, and a device success rate of 90 %. 
One-year mortality was 17.5 %, and the patients were New 
York Hear Association functional class I or II. It was con-
cluded that TAV-in-BAV is feasible with encouraging short- 
and intermediate-term clinical outcomes. However, a high 
incidence of post-implantation aortic regurgitation was 
observed of 28 %, which appears to be mitigated by MSCT-
based TAV sizing (17 %). Since MSCT-based TAV sizing 
was clearly associated with reduced para-valvular regurgi-
tation, MSCT should be considered a mandatory element of 
patient screening for TAV-in-BAV, certainly in view of the 
suboptimal echocardiographic results. In an accompanying 
Editorial by Colombo and Latib [14], it was stated that the 
incidence of significant aortic regurgitation, even with full 
MSCT evaluation, is still too high to extend TAVR to BAV 
unless the patient is truly inoperable or has an unacceptably 
high surgical risk. On the other hand, the Editorial reports 
that the current study sets a benchmark for next-generation 
TAVR devices demonstrating the feasibility of TAV-in-BAV.
To summarise, to diagnose patients with BAV, echo-
cardiography remains the first choice. However, when 
the echocardiograms are difficult to analyse or for careful 
evaluation of the progression of aortic diameters, CMR is 
very useful to come to a diagnosis. MSCT is increasingly 
being used to accurately size the aortic root diameters. The 
recent study by Mylotte et al. [12] is the first large multi-
centre analysis of TAV implantation in patients with signifi-
cant BAV stenosis or regurgitation. TAV-in-BAV proved to 
be feasible with encouraging short- and intermediate-term 
clinical outcomes, but the relatively high incidence (28 %) 
of post-implantation aortic regurgitation is of serious con-
cern. Therefore, longer-term follow-up of a larger cohort of 
patients is required to more completely assess the efficacy 
and durability of TAV implantation in patients with bicuspid 
disease.
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